Sheaff Brock Investment Advisors LLC lessened its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 23.9% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,800 shares of the medical research company’s stock after selling 3,400 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Exact Sciences Corporation were worth $382,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Suntrust Banks Inc. boosted its position in shares of Exact Sciences Corporation by 1.5% in the first quarter. Suntrust Banks Inc. now owns 18,478 shares of the medical research company’s stock valued at $436,000 after acquiring an additional 277 shares during the period. Stifel Financial Corp boosted its position in shares of Exact Sciences Corporation by 1.5% in the first quarter. Stifel Financial Corp now owns 21,475 shares of the medical research company’s stock valued at $506,000 after acquiring an additional 310 shares during the period. Prudential Financial Inc. boosted its position in shares of Exact Sciences Corporation by 3.0% in the first quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock valued at $263,000 after acquiring an additional 320 shares during the period. Lincoln National Corp boosted its position in shares of Exact Sciences Corporation by 7.8% in the second quarter. Lincoln National Corp now owns 10,104 shares of the medical research company’s stock valued at $357,000 after acquiring an additional 728 shares during the period. Finally, Baker Avenue Asset Management LP boosted its position in shares of Exact Sciences Corporation by 2.3% in the first quarter. Baker Avenue Asset Management LP now owns 35,251 shares of the medical research company’s stock valued at $833,000 after acquiring an additional 795 shares during the period. 85.22% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/09/11/sheaff-brock-investment-advisors-llc-sells-3400-shares-of-exact-sciences-corporation-exas.html.

In other Exact Sciences Corporation news, Director Thomas D. Carey purchased 2,500 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was purchased at an average price of $37.71 per share, for a total transaction of $94,275.00. Following the transaction, the director now owns 60,858 shares in the company, valued at approximately $2,294,955.18. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP D Scott Coward sold 1,987 shares of Exact Sciences Corporation stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $35.21, for a total value of $69,962.27. Following the sale, the senior vice president now owns 57,603 shares of the company’s stock, valued at approximately $2,028,201.63. The disclosure for this sale can be found here. In the last quarter, insiders have sold 129,291 shares of company stock valued at $5,288,181. Corporate insiders own 4.00% of the company’s stock.

Exact Sciences Corporation (EXAS) opened at 42.46 on Monday. The firm’s market cap is $5.06 billion. The company has a 50-day moving average price of $39.48 and a 200-day moving average price of $31.77. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $43.29.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.10. The firm had revenue of $57.65 million during the quarter, compared to the consensus estimate of $47.73 million. Exact Sciences Corporation had a negative return on equity of 36.36% and a negative net margin of 83.08%. On average, equities research analysts forecast that Exact Sciences Corporation will post ($1.18) EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on the stock. Vetr raised shares of Exact Sciences Corporation from a “sell” rating to a “hold” rating and set a $36.55 target price for the company in a research report on Tuesday, July 25th. Lake Street Capital boosted their target price on shares of Exact Sciences Corporation from $30.00 to $41.00 and gave the company a “hold” rating in a research report on Wednesday, July 26th. Roth Capital boosted their target price on shares of Exact Sciences Corporation from $40.00 to $46.00 and gave the company a “buy” rating in a research report on Wednesday, July 26th. BTIG Research reissued a “buy” rating and issued a $45.00 target price (up previously from $35.00) on shares of Exact Sciences Corporation in a research report on Monday, July 17th. Finally, Craig Hallum reissued a “buy” rating and issued a $46.00 target price (up previously from $41.00) on shares of Exact Sciences Corporation in a research report on Wednesday, July 26th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $40.98.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.